 Home > Encyclopedia > Ribostamycin sulfate

Ribostamycin sulfate

Ribostamycin sulfate structure

CAS No:
53797-35-6
Formula:
C17H34N4O10.xH2O4S
Chemical Name:
Ribostamycin sulfate
Synonyms:
D-Streptamine,O-2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl-(1→4)-O-[β-D-ribofuranosyl-(1→5)]-2-deoxy-,sulfate (1:?);D-Streptamine,O-2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl-(1→4)-O-[β-D-ribofuranosyl-(1→5)]-2-deoxy-,sulfate (salt);Vistamycin sulfate;Ribostamycin sulfate;Ibistacin;Ribostamin;Mandamycine;Ribomycine
Categories:
Active Pharmaceutical Ingredients > Antibiotics

Description

Ribostamycin is a broad-spectrum antimicrobial, inhibits bacterial protein synthesis at the level of 30S and 50S ribosomal subunit binding, also inhibits the chaperone activity of protein disulfide isomerase (PDI), used in pharmacokinetic and nephrotoxicity studies

Ribostamycin sulfate Basic Attributes

Molecular Weight：

474.44238

Exact Mass：

552.194885

EC Number：

258-783-1

DSSTox ID：

DTXSID8045480

Characteristics

PSA：

345.36000

XLogP3：

-3.42310

Appearance：

COA

Density：

1.6g/cm3

Melting Point：

175-180 C

Boiling Point：

907.6°C at 760 mmHg

Flash Point：

>110°(230°F)

Water Solubility：

H2O: soluble 50mg/mL

Storage Conditions：

2-8°C

Toxicity：

LD50 i.v. in mice: 225 mg/kg (Shomura)

Specific rotation：

D20 +39° (c = 1)

Safety Information

Packing level：

Ⅲ

Transport codes：

2811

wgk germany：

hazard class code：

61-20/21/22-36/38

safety instructions：

53-22-36/37/39-45-37/39-26

RTECS Number：

WK2300000

Marks：

T,Xi

Precautionary statement(s)：

P201-P280-P308 + P313

Hazard Statements：

H312-H332-H360

GHS Classification：

|Danger|H312 (97.44%): Harmful in contact with skin [Warning Acute toxicity, dermal]|P201, P202, P261, P271, P280, P281, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P363, P405, and P501|Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Ribostamycin sulfate Use and Manufacturing

Antibacterial;Ribosomal protein synthesis inhibitor

Computed Properties

Molecular Weight:552.6
Hydrogen Bond Donor Count:12
Hydrogen Bond Acceptor Count:18
Rotatable Bond Count:6
Exact Mass:552.19487301
Monoisotopic Mass:552.19487301
Topological Polar Surface Area:345
Heavy Atom Count:36
Complexity:674
Defined Atom Stereocenter Count:14
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Aminoglycoside antibiotics, the antibacterial spectrum is similar to kanamycin, but the antibacterial effect is weaker. It has good antibacterial activity against Escherichia coli, Klebsiella, Proteus and other Enterobacteriaceae, and also has good effects on some Staphylococci (methicillin-sensitive strains), Neisseria gonorrhoeae, and Neisseria meningitidis. It has a weak effect on Mycobacterium tuberculosis and Streptococcus, and has no effect on Pseudomonas aeruginosa and anaerobic bacteria. Bacteria have cross-resistance to this product and kanamycin. It mainly binds to the 30S subunit of the bacterial ribosome and inhibits bacterial protein synthesis. The toxicity is lower than that of kanamycin.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Ribomycin Sulfate for Injection
Ingredients	Ribomycin sulfate.
Indication	1. This product combined with other aminoglycosides or applied topically or systemically may increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. This product combined with neuromuscular blocking drugs may aggravate neuromuscular blocking effects, leading to muscle weakness, respiratory depression, etc. This product combined with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), etc., or applied topically or systemically successively, may increase ototoxicity and nephrotoxicity. 3. This product combined with cephalothin or cefazolin topically or systemically may increase nephrotoxicity. 4. This product combined with polymyxin injections, or applied topically or systemically successively, may increase nephrotoxicity and neuromuscular blocking effects. 5. Other nephrotoxic and ototoxic drugs should not be used in combination with this product or applied sequentially to avoid aggravating nephrotoxicity or ototoxicity.
Specifications	1g (1 million units)
Manufacturer	CSPC OUYI Pharmaceutical Co., Ltd.

Ribomycin Sulfate for Injection
Ingredients	Ribomycin sulfate.
Indication	1. This product combined with other aminoglycosides or applied topically or systemically may increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. This product combined with neuromuscular blocking drugs may aggravate neuromuscular blocking effects, leading to muscle weakness, respiratory depression, etc. This product combined with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), etc., or applied topically or systemically successively, may increase ototoxicity and nephrotoxicity. 3. This product combined with cephalothin or cefazolin topically or systemically may increase nephrotoxicity. 4. This product combined with polymyxin injections, or applied topically or systemically successively, may increase nephrotoxicity and neuromuscular blocking effects. 5. Other nephrotoxic and ototoxic drugs should not be used in combination with this product or applied sequentially to avoid aggravating nephrotoxicity or ototoxicity.
Specifications	1.0g (1 million units)
Manufacturer	Merro Pharmaceutical Co., Ltd.

Ribomycin Sulfate Injection
Ingredients	The main component of this product is ribofuranosyl sulfate, and its chemical name is: O-3-D ribofuranosyl-(15)-0-[a-2,6-dideoxy-D-pyranose-glucopyranose-(14)]-a-deoxystreptamine sulfate
Indication	1. When used in combination with plasma substitutes such as dextran, glucose, sodium alginate, and other nephrotoxic drugs, renal toxicity may be increased. 2. When used in combination with other aminoglycosides or when applied topically or systemically one after the other, the possibility of ototoxicity, nephrotoxicity, and neuromuscular blocking effects may be increased. 3. When used in combination with neuromuscular blockers, the neuromuscular blocking effect may be aggravated, leading to muscle weakness, respiratory depression, or respiratory paralysis. 4. When used in combination with capreomycin, cisplatin, uric acid, furosemide, or vancomycin, or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased. 5. When used topically or systemically with cephalothin, renal toxicity may be increased. 6. When used in combination with polymyxin injections, or when applied topically or systemically one after the other, renal toxicity and neuromuscular blocking effects may be increased.
Specifications	2ml:0.5g (500,000 units)
Manufacturer	Shandong Xinhua Pharmaceutical Company Limited

See More Related Drugs

Registered Holders

Yueyang Tonglian Pharmaceutical Co., Ltd.

China
Active
Wuxi Fortune Pharmaceutical Co., Ltd.

China
Active

Recommended Suppliers of Ribostamycin sulfate

Shandong Airuike Chemical Co., Ltd. Contact Supplier

CN
2 YRS

Business licensed

Trader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE

Ribostamycin sulfate53797-35-6

CAS No.: 53797-35-6

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
Hangzhou Dawn Ray Pharmaceutical Co.,Ltd Contact Supplier

CN
5 YRS

Business licensed Certified factory

Manufactory Supplier of D-Biotin,Tobramycin base,L(-)-Carnitine base,Polymyxin B sulfate USP,Kanamycin sulfate monohydrate,Finasteride 99% USP

Ribostamycin sulfate salt

CAS No.: 53797-35-6

Inquiry